The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2025 | The current standard of care for IDH-mutated AML & combinations being explored
Jennifer Marvin-Peek, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the current standard of care for patients with IDH-mutated acute myeloid leukemia (AML), highlighting two regimens: azacitidine in combination with venetoclax and azacitidine in combination with ivosidenib. Dr Marvin-Peek then discusses the potential for combining all of these agents to deepen remissions and extend overall survival. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
